Clinical Trials Arena on MSN

UCB’s Bimzelx bests Skyrizi in Phase III PsA study, but analysts sceptical

While this result affirms Bimzelx’s efficacy in PsA, analysts do not believe this readout will have a notable impact on the ...

Did Positive Phase 3 SKYRIZI Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?

In early March 2026, AbbVie reported positive topline Phase 3 AFFIRM data showing risankizumab (SKYRIZI) subcutaneous ...
St. Louis American

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie’s Portfolio Across Inflammatory Bowel Disease

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately ...

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) ...
Seeking Alpha

AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis

NORTH CHICAGO, Ill., Aug. 28, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and ...
Benzinga.com

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

AbbVie Inc. (NYSE: ABBV) reported fourth-quarter 2025 sales of $16.62 billion on Wednesday, beating the consensus of $16.42 billion. Sales increased 10% on a reported basis or 9.5% on an operational ...